0001458511-17-000003.txt : 20171018 0001458511-17-000003.hdr.sgml : 20171018 20171018151927 ACCESSION NUMBER: 0001458511-17-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20171018 DATE AS OF CHANGE: 20171018 EFFECTIVENESS DATE: 20171018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intellipharmaceutics International Inc. CENTRAL INDEX KEY: 0001474835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-296978 FILM NUMBER: 171142589 BUSINESS ADDRESS: STREET 1: 30 WORCESTER ROAD CITY: TORONTO STATE: A6 ZIP: M9W 5X2 BUSINESS PHONE: 416-798-3001 MAIL ADDRESS: STREET 1: 30 WORCESTER ROAD CITY: TORONTO STATE: A6 ZIP: M9W 5X2 FORMER COMPANY: FORMER CONFORMED NAME: IntelliPharmaCeutics International Inc. DATE OF NAME CHANGE: 20091020 D 1 primary_doc.xml X0708 D LIVE 0001474835 Intellipharmaceutics International Inc. 30 WORCESTER ROAD TORONTO A6 ONTARIO, CANADA M9W 5X2 416-798-3001 ONTARIO, CANADA IntelliPharmaCeutics International Inc. Corporation true Isa Odidi 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Executive Officer Director Amina Odidi 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Executive Officer Director Eldon R. Smith 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Director Kenneth Keirstead 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Director Bahadur Madhani 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Director Andrew Patient 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Executive Officer Michael Campbell 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Executive Officer Pharmaceuticals $1,000,001 - $5,000,000 06b false 2017-10-11 false true true false 0 H.C. Wainwright Co., LLC 375 None None 430 Park Avenue 4th Floor New York NY NEW YORK 10022 NJ NEW JERSEY NY NEW YORK false 2522728 2522728 0 Represents the aggregate warrant exercise price for the warrants covered by this Form D, which were issued in a private placement ("PP") conducted concurrently with a registered direct offering ("RDO") of common shares not the subject of this Form D. false 6 280000 0 H.C. Wainwright Co., LLC ("Wainwright") received the above sales commissions, and $65,000 in expense reimbursements in connection with the RDO and the PP of the warrants. Wainwright also received warrants to purchase an aggregate of 181,818 common shares. 0 false Intellipharmaceutics International Inc. Andrew Patient Andrew Patient CFO 2017-10-18